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Background: Our work has been carried out in the context of the therapeutic failure in ovarian carcinoma, which
remains the leading cause of death by gynecologic malignancy. In these tumours, recurrence and subsequent
acquired chemoresistance constitute major hurdles to successful therapy. Here we studied the interest of a member
of the tripentone chemical family, MR22388, for the treatment of chemoresistant ovarian cancer cells.
Findings: MR22388 activity has been assessed in vitro on cisplatin-resistant (SKOV3 and IGROV1-R10) ovarian cancer
cell lines by conventional analysis, alone or combined to a BH3-mimetic molecule, ABT-737. MR22388 exerts its
activity on cisplatin resistant cells, and we showed that it induces a decrease of the Mcl-1 anti-apoptotic protein
expression. Considering our previous work demonstrating that the efficiency of Bcl-xL targeting strategies is
conditioned to the concomitant inhibition of Mcl-1 we studied the interest of the association of this MR22388 with
ABT-737, and showed that this combination was highly cytotoxic in chemoresistant cells.
Conclusions: This work thus opens new perspectives for the use of this promising molecule for the treatment of
highly chemoresistant ovarian cancer cells and for sensitization of emerging Bcl-xL targeting strategies such as the
use of BH3-mimetic molecules.
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Background
Ovarian cancer is the leading cause of death by
gynecological malignancies [1]. Standard first line treat-
ment (debulking surgery followed by platinum/taxane
based chemotherapy) and various second line chemo-
therapies appear generally unable to cure the disease
[2], the therapeutic failure being mainly due to a multi-
factorial intrinsic or acquired chemoresistance [3,4].
Thus, there is an urgent need of new strategies for the
treatment of refractory disease.* Correspondence: l.poulain@baclesse.fr
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reproduction in any medium, provided the orOur previous work showed that platinum resistance was
associated with the capacity of ovarian cancer cells to main-
tain a high level of two anti-apoptotic proteins of the Bcl-2
family, Bcl-xL and Mcl-1 [5]. These proteins cooperate to
protect ovarian cancer cells against apoptotic cell death and
their concomitant inhibition leads to massive cell death
even in the absence of chemotherapy. We also demon-
strated that Mcl-1 down-regulation or inactivation leads to
a strong sensitization to Bcl-xL-targeting strategies, such as
treatment by the BH3-mimetic ABT-737 [6-8].
The 8H-thieno[2,3-b]pyrrolizinones, also named
tripentones, constitute a promising family of novel
compounds for cancer therapeutics [9]. Among them,
the 3-(3-hydroxy-4-methoxyphenyl)-8H-thieno[2,3-b]
pyrrolizin-8-one (MR22388, abbreviated TP) has
shown a significant cell growth inhibitory activity inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lines, including ovarian carcinoma cells, and can be
considered as the lead of this family [9,10]. To date,
the precise mechanisms of action of MR22388 remain
unknown.
Here we investigated the cytotoxic activity of MR22388
on cisplatin-resistant ovarian carcinoma cells and its poten-
tial as a modulator of the expression or activity of Bcl-xL
and Mcl-1. We also tested its cytotoxic activity when used
in combination with ABT-737.
Materials & methods
Chemicals
MR22388 [11] was purchased from Syntheval (Caen,
France). ABT-737 was purchased from Selleckchem
(Euromedex, Souffelweyersheim, France).
Cell culture and treatment
SKOV3 cell line obtained from ECACC (Cerdic, Nice,
France) and chemoresistant IGROV1-R10 subline obtained
from IGROV1 parental cells [12] were cultured as described
[13]. Cells were continuously treated with MR22388 or
ABT-737. Cell viability was determined by Trypan blue ex-
clusion assay using Cedex XS device (Roche, France).
Real-time cellular activity assay (xCELLigence)
Compound-mediated cytotoxicity was monitored using
Real-Time Cell Analyzer (RTCA) multi-plate Instrument,
xCELLigence System (Roche Applied Science, Mannheim,
Germany) [13]. The cell index reflects changes in cell via-
bility as described elsewhere [14]. Briefly, cells were left to
grow for 24 h before treatment in 96-well E-Plate and im-
pedance was continuously measured until the end of the
treatment. Standard deviations of well replicates were ana-
lyzed with the RTCA Software.
RNA isolation and quantitative reverse transcripase-
PCR (RT-PCR) were performed as described elsewhere
[7].
Determination of cellular DNA content was performed
by flow cytometry as described elsewhere [13].
Preparation of cell extracts and western blot ana-
lysis were performed as described elsewhere [13]. The fol-
lowing antibodies were used: PARP, Caspase-3 and Bcl-xL
(Cell Signaling Technology by Ozyme, Saint-Quentin-en-
Yvelines, France), MCL-1 (Santa Cruz by CliniSciences,
Nanterre, France), phospho(Ser62)-Bcl-xL (AssaybioTech
by Tebu-bio, Le Perray-en-Yvelines, France) and Actin
(Sigma-Aldrich, Saint-Quentin Fallavier, France).
Results
Effect of MR22388 on the proliferation and apoptosis of
SKOV3 and IGROV1-R10 cisplatin-resistant cell lines
MR22388 induced a strong cytostatic effect from 100 nM
on both cell lines, with a slight dose-effect between 100 and1000 nM (Figures 1A and 1B). Moreover, MR22388 expos-
ure induced an S phase elongation in IGROV1-R10 cells
and a G2-M phase blockade in both cell lines (Figure 1C).
Massive cell death occurred in a dose-dependent manner
after a 72 h exposure to MR22388 (Figure 1C), as shown by
cell detachment and sub-G1 peak appearance on DNA con-
tent histograms. PARP and Caspases 9 and 3 cleavages have
been observed in a time and concentration dependent man-
ner (data not shown). However, the exposure to 100nM
MR22388 allowed a slow recovery of a proliferating cell
population in both cell lines (Figure 1A). At this concentra-
tion, MR22388 also induced a transient cell detachment
and rounding of SKOV3 cells that was not associated to
massive cell death, responsible for a transient decrease cell
index on impedancemetry curves (Figure 1B, left panel).
After 24 h, the cells recovered a normal adhesion but were
unable to proliferate, the cell index thus reaching a plateau
after 48 h.
MR22388 modulates MCL-1 expression and Bcl-xL
phosphorylation
A 24 h exposure to MR22388 led to a half-decrease of Mcl-
1 expression in both cell lines from 100 nM (Figure 2A and
2B), in absence of cell death. This Mcl-1 protein disappear-
ance was not associated to transcriptionnal down-regulation
(Figure 2C). Otherwise, at the same time, MR22388 did not
modified Bcl-xL expression but induced the appearance of a
slower-migrating Bcl-xL band evocative of a phosphorylated
form (Figure 2D). We showed that this band was at least in
part constituted by a Ser62-phosphorylated form of Bcl-xL
(Figure 2E).
MR22388 sensitizes to ABT-737
After a 24 h exposure to MR22388 (when Mcl-1 expres-
sion is decreased), cells were treated by ABT-737.
Whereas 100 nM MR22388 alone allowed the recovery
of proliferative population, as previously evocated, its
association with ABT-737 suppressed this recovery in
both cell lines (Figure 3A and 3E), leading to the
complete annihilation of the population. In contrast,
ABT-737 had no (SKOV3) or little (IGROV1-R10) effect
as a single agent.
This strong cytotoxic effect of the association is con-
firmed by morphological observations (Figure 3B and 3C).
Moreover, the combination MR22388/ABT-737 led to a
complete PARP and Caspase-3 cleavage, evocative of
massive cell death (Figure 3D and F), whereas MR22388
or ABT-737 alone did not. Similar results were obtained
on both cell lines using siRNA directed against Bcl-xL in-
stead of ABT-737 (data not shown).
Discussion
The tripentone MR22388 has been identified as a potential
anti-tumour agent and demonstrated strong in vitro anti-
Figure 1 MR22388 exerts a cytostatic and cytotoxic effect on cisplatin-resistant cell lines. Exponentially growing SKOV3 and IGROV1-R10
cells were treated with MR22388 at 10, 100 and 1000 nM. [A] Percentages of cell viability, assessed by trypan blue exclusion test after 24, 48 and
72 h exposure to MR22388, as compared to the initial number of viable cells in the flask. [B] Real time analysis of cellular activity of MR22388
obtained using the xCELLigence system. Cells were grown for 24 h, then treated with MR22388 (10, 100 and 1000 nM). Cell index was recorded
every 2 h. The results are the mean of three replicates. [C] DNA content histograms and cellular morphologies, assessed 72 h after the beginning
of the MR22388 exposure.
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[10,15,16]. We observed similar effects in two chemoresistant
ovarian cancer cell lines. MR22388 exposure induced strong
cell cycle perturbations and triggered apoptosis in a concen-
tration dependent manner.
MR22388 has been shown to be able to exert various ef-
fects such as anti-tubulin effects [15] and inhibition of GSK3,
CDK1 [11] and showed an affinity for FLT3-ITD [10].
However, whatever are the MR22388 direct targets,
we focused our attention on possible indirect effects ofFigure 2 MR22388 modulates MCL-1 expression and Bcl-xL phosphor
24 h. [A] PARP cleavage and Mcl-1 expression, analyzed by western blot. A
Image J software. The relative intensity of each lane was calculated as com
PCR. [D] Bcl-xL expression and [E] Ser62-phospho-Bcl-xL detected by westeMR22388 on Bcl-2 family members since we previously
demonstrated that anti-apoptotic proteins Bcl-xL and
Mcl-1 cooperate to protect ovarian carcinoma cells
against apoptosis. Indeed, their concomitant inhibition
leads to massive cell death, even in absence of chemo-
therapy [6,7]. Here we showed that Mcl-1 protein (but
not mRNA) was drastically decreased in both cell lines
after exposure to MR22388.
Mcl-1 is submitted to a rapid turnover, and the control
of its expression could involve both transcriptional andylation. Cells were treated with MR22388 (100 and 1000 nM) during
ctin was used as loading control. [B] Mcl-1 expression quantified by
pared to the DMSO sample. [C] Mcl-1 mRNA was quantified by qRT-
rn blot.
Figure 3 MR22388 sensitizes ovarian cancer cells to ABT-737. Real time analysis of cellular activity of the combination of MR22388 and ABT-
737 was performed using the xCELLigence system. Cells were grown for 24 h, then treated with MR22388 (10, 100 and 1000 nM). 24 h after the
beginning of the exposure, IGROV1-R10 (top panel) and SKOV3 (bottom panel) were treated by 10 μM ABT-737. [A,E] Cell index, recorded every
30 min. The results are the mean of three replicates. [B] 4 h after the ABT-737 exposure, IGROV1-R10 DNA content histograms and cellular
morphology were assessed. [C] 72 h after ABT-737 exposure, IGROV1-R10 cellular morphology was assessed. PARP and Caspase 3 cleavages were
determined by western blot in IGROV1-R10 [D] and SKOV3 cells [F].
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Bcl-2 family members can favour its stabilization or its
degradation, depending of the partner [17]. Mcl-1 degrad-
ation can involve the proteasome pathway following JNK
and GSK3 associated Mcl-1 phosphorylations [18], but can
also be a consequence of caspases activity [19]. This last
possibility has been excluded in our model since Mcl-1
was decreased even in condition in which apoptosis is not
detected (24 h).
We also detected the appearance of the ser62-
phosphorylated form of Bcl-xL. Phosphorylated forms
have been previously described by others in response
to various stresses [20,21]. Ser62-phosphorylated form
has been associated with a loss of anti-apoptotic func-
tion [22] and to the appearance of a capacity of
phospho-Bcl-xL to translocate in the nucleus to lead to
a G2-M cell cycle arrest. Moreover, these events as well
as Bcl-xL ser62-phosphorylation have been related to
the activation of JNK, among other kinases [23].
Interestingly, it has also been shown that phosphor-
ylation of Mcl-1 by JNK (itself activated by various
apoptotic stresses) is required for subsequent docking
of GSK3 on Mcl-1 allowing Mcl-1 phosphorylation,
ubiquitinylation and degradation [24].
Altogether, our observations (G2-M blockade, Mcl-1
expression decrease and phosphorylation of Bcl-xL on
ser62) argue in favour of an activation of cell-death re-
lated signalling pathways such as JNK pathway by
MR22388.
In any case, the capacity of MR22388 to inhibit Mcl-1
could be positively exploited in the context of Bcl-xL-
targeting strategies. Here we showed that the association
of MR22388 with ABT-737 was highly cytotoxic, in a
manner correlated with the disappearance of Mcl-1.
Here we could hypothesize the existence of cooper-
ation between tripentone that decrease Mcl-1 expression
level and ABT-737 that inhibits Bcl-xL and consequently
releases the BH3-only protein Bim from Bcl-xL. Bim sub-
sequently becomes able to inactivate residual Mcl-1 pro-
tein, and to activate Bax/Bak apoptotic proteins. Indeed,
a shuttling of Bim sequestration between Mcl-1 and Bcl-xL,
depending of their respective expression level has been re-
cently described [25], Bcl-xL being here presented as a de-
terminant of the response to Mcl-1 inhibiting agents. In
our model, MR22388 and ABT-737 should thus be consid-
ered as co-sensitizer agents.
In summary, although MR22388 activity is not yet
fully understood, its interesting effect on the modulation
of Bcl-2 family proteins could be positively exploited in
the context of Bcl-xL-targeting strategies such as emer-
ging BH3-mimetic molecules.
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